
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6668751/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fenotipos de linfocitos periféricos en las enfermedades de Alzheimer y Parkinson. NeurologÃa, 2022, 37, 110-121.	0.3	8
2	Evaluation of recombinant glutathione transferase 26ÂkDa, thioredoxin-1, and endophilin B1 of Taenia solium in the diagnosis of human neurocysticercosis. Acta Tropica, 2022, 227, 106294.	0.9	0
3	Multiple-bead assay for the differential serodiagnosis of neglected human cestodiases: Neurocysticercosis and cystic echinococcosis. PLoS Neglected Tropical Diseases, 2022, 16, e0010109.	1.3	2
4	Role of Systemic and Nasal Clucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection. Archives of Medical Research, 2021, 52, 143-150.	1.5	5
5	Zoonotic Taenia infections with focus on cysticercosis due to Taenia solium in swine and humans. Research in Veterinary Science, 2021, 134, 69-77.	0.9	13
6	Natural history of extraparenchymal neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1218-1225.	0.7	5
7	Approaches to Understanding <scp>COVID</scp> â€19 and its Neurological Associations. Annals of Neurology, 2021, 89, 1059-1067.	2.8	16
8	Inflammation in neurocysticercosis: clinical relevance and impact on treatment decisions. Expert Review of Anti-Infective Therapy, 2021, 19, 1503-1518.	2.0	11
9	Temporal lobe epilepsy: Evaluation of central and systemic immune-inflammatory features associated with drug resistance Seizure: the Journal of the British Epilepsy Association, 2021, 91, 447-455.	0.9	9
10	Effect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by Taenia crassiceps in BALB/c mice: In vitro and in vivo evaluation. Experimental Parasitology, 2020, 208, 107801.	0.5	16
11	Could Differences in Infection Pressure Be Involved in Cysticercosis Heterogeneity?. Trends in Parasitology, 2020, 36, 826-834.	1.5	21
12	Intranasal Dexamethasone Reduces Mortality and Brain Damage in a Mouse Experimental Ischemic Stroke Model. Neurotherapeutics, 2020, 17, 1907-1918.	2.1	15
13	Extraparenchymal human neurocysticercosis induces autoantibodies against brain tubulin and MOG35–55 in cerebral spinal fluid. Journal of Neuroimmunology, 2020, 349, 577389.	1.1	3
14	Diagnostic value of glycoprotein band patterns of three serologic enzyme-linked immunoelectrotransfer blot assays for neurocysticercosis. Parasitology Research, 2020, 119, 2521-2529.	0.6	2
15	DNA methylation of the RE-1 silencing transcription factor in peripheral blood mononuclear cells and gene expression of antioxidant enzyme in patients with late-onset Alzheimer disease. Experimental Gerontology, 2020, 136, 110951.	1.2	9
16	Intrasellar cysticercosis cyst treated with a transciliary supraorbital keyhole approach – A case report. , 2020, 11, 436.		6
17	Optimal Treatment for Subarachnoid Neurocysticercosis: Closer, but Not There yet. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1-2.	0.6	2
18	Extraparenchymal neurocysticercosis: a challenge in treatment and in clinical management. Revista Del Centro De InvestigaciÓn - Universidad La Salle, 2020, 13, 9-18.	0.1	0

#	Article	IF	CITATIONS
19	Neurocisticercosis extraparenquimatosa: reto terapéutico A propósito de un caso de la glándula parótida. Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico, 2020, 63, 19-27.	0.0	0
20	Immunodiagnosis of human neurocysticercosis: comparative performance of serum diagnostic tests in Mexico. Parasitology Research, 2019, 118, 2891-2899.	0.6	13
21	Erratum - Effect of Albendazole Treatment in an Experimental Model of Neurocysticercosis-Induced Hydrocephalus. Brazilian Neurosurgery, 2019, 38, 077-077.	0.0	0
22	Neurocysticercosis and HIV Infection: what can we learn from the published literature?. Arquivos De Neuro-Psiquiatria, 2019, 77, 357-365.	0.3	10
23	Hydrocephalus in Neurocysticercosis: Challenges for Clinical Practice and Basic Research Perspectives. World Neurosurgery, 2019, 126, 264-271.	0.7	13
24	Association of <i>TRAF1/C5</i> Locus Polymorphisms with Epilepsy and Clinical Traits in Mexican Patients with Neurocysticercosis. Infection and Immunity, 2019, 87, .	1.0	8
25	Development of point-of-care tests for <i>Taenia solium</i> : one of the ways to obtain a better diagnosis and therapeutic management of patients, and to reach eradication. Pathogens and Global Health, 2019, 113, 323-324.	1.0	1
26	Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis. Journal of Clinical Pharmacology, 2019, 59, 548-556.	1.0	26
27	Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury. Annals of the New York Academy of Sciences, 2019, 1437, 43-56.	1.8	59
28	Neurocysticercosis: mimics and chameleons. Practical Neurology, 2019, 19, 88-95.	0.5	9
29	Neurocysticercosis and HIV Infection. Arquivos De Neuro-Psiquiatria, 2019, 77, 837-837.	0.3	0
30	Neurocysticercosis: the good, the bad, and the missing. Expert Review of Neurotherapeutics, 2018, 18, 289-301.	1.4	36
31	No association of IL2, IL4, IL6, TNF , and IFNG gene polymorphisms was found with Taenia solium human infection or neurocysticercosis severity in a family-based study. Human Immunology, 2018, 79, 578-582.	1.2	6
32	Human Extraparenchymal Neurocysticercosis: The Control of Inflammation Favors the Host…but Also the Parasite. Frontiers in Immunology, 2018, 9, 2652.	2.2	22
33	New guidelines for the diagnosis and treatment of neurocysticercosis: a difficult proposal for patients in endemic countries. Expert Review of Neurotherapeutics, 2018, 18, 743-747.	1.4	10
34	Genetics of Infections and Diseases Caused by Human Parasites Affecting the Central Nervous System. , 2018, , 57-68.		0
35	Treatment-Resistant Human Extraparenchymal Neurocysticercosis: An Immune-Inflammatory Approach to Cysticidal Treatment Outcome. NeuroImmunoModulation, 2018, 25, 103-109.	0.9	1
36	Persistent <i>Taenia solium</i> Cysticercosis In the State of Morelos, Mexico: Human and Porcine Seroprevalence. Journal of Parasitology, 2018, 104, 465-472.	0.3	4

Agnès Fleury

#	Article	IF	CITATIONS
37	Recovery from an acute systemic and central LPS-inflammation challenge is affected by mouse sex and genetic background. PLoS ONE, 2018, 13, e0201375.	1.1	30
38	Reply. Annals of Neurology, 2017, 81, 474-475.	2.8	0
39	Effect of Transforming Growth Factor-β upon Taenia solium and Taenia crassiceps Cysticerci. Scientific Reports, 2017, 7, 12345.	1.6	27
40	Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation. Clinical and Experimental Immunology, 2017, 190, 304-314.	1.1	31
41	Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features. PLoS Neglected Tropical Diseases, 2017, 11, e0005646.	1.3	68
42	Reproducibility of Diagnostic Criteria for Ventricular Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1952-1952.	0.6	2
43	Interleukin 10 and dendritic cells are the main suppression mediators of regulatory T cells in human neurocysticercosis. Clinical and Experimental Immunology, 2016, 183, 271-279.	1.1	31
44	Immunopathology in <i>Taenia solium</i> neurocysticercosis. Parasite Immunology, 2016, 38, 147-157.	0.7	38
45	Reply. Annals of Neurology, 2016, 80, 954-954.	2.8	0
46	Electric stimulation of the vagus nerve reduced mouse neuroinflammation induced by lipopolysaccharide. Journal of Inflammation, 2016, 13, 33.	1.5	80
47	New diagnostic criteria for neurocysticercosis: Reliability and validity. Annals of Neurology, 2016, 80, 434-442.	2.8	102
48	A lateral flow assay (LFA) for the rapid detection of extraparenchymal neurocysticercosis using cerebrospinal fluid. Experimental Parasitology, 2016, 171, 67-70.	0.5	13
49	Spinal Taenia solium cysticercosis in Mexican and Indian patients: a comparison of 30-year experience in two neurological referral centers and review of literature. European Spine Journal, 2016, 25, 1073-1081.	1.0	14
50	Clinical Symptoms, Imaging Features and Cyst Distribution in the Cerebrospinal Fluid Compartments in Patients with Extraparenchymal Neurocysticercosis. PLoS Neglected Tropical Diseases, 2016, 10, e0005115.	1.3	32
51	In response: Multifactorial basis of epilepsy in patients with neurocysticercosis. Epilepsia, 2015, 56, 975-976.	2.6	1
52	Taenia solium: Development of an Experimental Model of Porcine Neurocysticercosis. PLoS Neglected Tropical Diseases, 2015, 9, e0003980.	1.3	23
53	Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia, 2015, 56, 177-183.	2.6	64
54	Relevance of 3D magnetic resonance imaging sequences in diagnosing basal subarachnoid neurocysticercosis. Acta Tropica, 2015, 152, 60-65.	0.9	55

Agnès Fleury

#	Article	IF	CITATIONS
55	Cysticercosis: A Preventable, but Embarrassing Neglected Disease Still Prevalent in Non-Developed Countries. , 2015, , 335-354.		3
56	Neurocysticercosis: Neurology and Neurobiology. , 2014, , 127-146.		1
57	Evolution, molecular epidemiology and perspectives on the research of taeniid parasites with special emphasis on Taenia solium. Infection, Genetics and Evolution, 2014, 23, 150-160.	1.0	20
58	Response to Letter: Aneurysm, ischemic stroke and cysticercosis. Clinical Neurology and Neurosurgery, 2014, 119, 136.	0.6	0
59	Neurocysticercosis: the effectiveness of the cysticidal treatment could be influenced by the host immunity. Medical Microbiology and Immunology, 2014, 203, 373-381.	2.6	25
60	Human neurocysticercosis: immunological features involved in the host's susceptibility to become infected and to develop disease. Microbes and Infection, 2013, 15, 524-530.	1.0	16
61	Development of the S3Pvac Vaccine Against MurineTaenia crassicepsCysticercosis: A Historical Review. Journal of Parasitology, 2013, 99, 693-702.	0.3	9
62	Development of the S3Pvac Vaccine Against Porcine <i>Taenia solium</i> Cysticercosis: A Historical Review. Journal of Parasitology, 2013, 99, 686-692.	0.3	29
63	Concurrent asymptomatic inflammatory aneurysm and ischemic stroke due to cysticercal arteritis. Clinical Neurology and Neurosurgery, 2013, 115, 2540-2542.	0.6	10
64	Neurocysticercosis. Neurology: Clinical Practice, 2013, 3, 118-125.	0.8	53
65	Neurocysticercosis: HP10 Antigen Detection Is Useful for the Follow-up of the Severe Patients. PLoS Neglected Tropical Diseases, 2013, 7, e2096.	1.3	46
66	Evidence-based guideline: Treatment of parenchymal neurocysticercosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2013, 81, 1474-1476.	1.5	2
67	Genetic variation in the Cytbgene of human cerebral Taenia soliumcysticerci recovered from clinically and radiologically heterogeneous patients with neurocysticercosis. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 914-920.	0.8	10
68	Cysticerci Drive Dendritic Cells to Promote <i>In Vitro</i> and <i>In Vivo</i> Tregs Differentiation. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	32
69	Control of Taenia Solium Transmission of Taeniosis and Cysticercosis in Endemic Countries: The Roles of Continental Networks of Specialists and of Local Health Authorities. , 2013, , .		4
70	Commentary. Journal of Neurosciences in Rural Practice, 2013, 4, 89-91.	0.3	0
71	Subarachnoid Hemorrhage in Neurocysticercosis. Neurologist, 2012, 18, 324-328.	0.4	7
72	Human Neurocysticercosis: In Vivo Expansion of Peripheral Regulatory T Cells and Their Recruitment in the Central Nervous System. Journal of Parasitology, 2012, 98, 142-148.	0.3	45

#	Article	IF	CITATIONS
73	Impact of Taenia solium neurocysticercosis upon endocrine status and its relation with immuno-inflammatory parameters. International Journal for Parasitology, 2012, 42, 171-176.	1.3	28
74	Neurocysticercosis: local and systemic immune-inflammatory features related to severity. Medical Microbiology and Immunology, 2012, 201, 73-80.	2.6	16
75	Neurocysticercosis is still prevalent in Mexico. Salud Publica De Mexico, 2012, 54, 632-636.	0.1	18
76	Human Neurocysticercosis: Comparison of Different Diagnostic Tests Using Cerebrospinal Fluid. Journal of Clinical Microbiology, 2011, 49, 195-200.	1.8	78
77	A Dramatic Case of Intraventricular Cysticercosis. Archives of Neurology, 2011, 68, 828-9.	4.9	4
78	Mechanisms Underlying the Induction of Regulatory T cells and Its Relevance in the Adaptive Immune Response in Parasitic Infections. International Journal of Biological Sciences, 2011, 7, 1412-1426.	2.6	50
79	Recombinant S3Pvac-phage anticysticercosis vaccine: Simultaneous protection against cysticercosis and hydatid disease in rural pigs. Veterinary Parasitology, 2011, 176, 53-58.	0.7	22
80	Determining the Burden of Neurological Disorders in Populations Living in Tropical Areas: Who Would Be Questioned? Lessons from a Mexican Rural Community. Neuroepidemiology, 2011, 36, 194-203.	1.1	26
81	Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Review of Anti-Infective Therapy, 2011, 9, 123-133.	2.0	135
82	Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurology, 2010, 10, 16.	0.8	43
83	Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 243-250.	0.7	86
84	Severe Cysticercal Meningitis: Clinical and Imaging Characteristics. American Journal of Tropical Medicine and Hygiene, 2010, 82, 121-125.	0.6	26
85	Neurocysticercosis, a Persisting Health Problem in Mexico. PLoS Neglected Tropical Diseases, 2010, 4, e805.	1.3	45
86	129-P: Susceptibility to neurocysticercosis (NC) is not associated with the IL-2 genotype (-330G/C) in Mexican mestizo patients. Human Immunology, 2009, 70, S76.	1.2	0
87	Cryptococcal Choroid Plexitis an Uncommon Fungal Disease. Case Report and Review. Canadian Journal of Neurological Sciences, 2009, 36, 117-122.	0.3	11
88	Parasite contamination of soil in households of a Mexican rural community endemic for neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 374-379.	0.7	16
89	Human and porcine neurocysticercosis: differences in the distribution and developmental stages of cysticerci. Tropical Medicine and International Health, 2008, 13, 697-702.	1.0	18
90	Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine, 2008, 26, 2899-2905.	1.7	67

#	Article	IF	CITATIONS
91	Preferential Growth of Taenia crassiceps Cysticerci in Female Mice Holds Across Several Laboratory Mice Strains and Parasite Lines. Journal of Parasitology, 2008, 94, 551-553.	0.3	31
92	Neurocysticercosis: detection of <i>Taenia solium</i> DNA in human cerebrospinal fluid using a semi-nested PCR based on HDP2. Annals of Tropical Medicine and Parasitology, 2008, 102, 317-323.	1.6	41
93	Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives. Current Topics in Medicinal Chemistry, 2008, 8, 424-433.	1.0	30
94	Spatial Distribution of Taenia solium Porcine Cysticercosis within a Rural Area of Mexico. PLoS Neglected Tropical Diseases, 2008, 2, e284.	1.3	44
95	Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 970-974.	0.9	78
96	Human Neurocysticercosis: Rightward Hemisphere Asymmetry in the Cerebral Distribution of a Single Cysticercus. Journal of Parasitology, 2007, 93, 1238-1240.	0.3	14
97	Further evaluation of the synthetic peptide vaccine S3Pvac againstTaenia soliumcysticercosis in pigs in an endemic town of Mexico. Parasitology, 2007, 134, 129-133.	0.7	30
98	Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine, 2007, 25, 1368-1378.	1.7	30
99	Impact of naturally acquired Taenia solium cysticercosis on the hormonal levels of free ranging boars. Veterinary Parasitology, 2007, 149, 134-137.	0.7	15
100	The immune response in <i>Taenia solium</i> cysticercosis: protection and injury. Parasite Immunology, 2007, 29, 621-636.	0.7	48
101	Neurocysticercosis. Pediatric Infectious Disease Journal, 2006, 25, 801-803.	1.1	60
102	Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Tropical Medicine and International Health, 2006, 11, 943-950.	1.0	44
103	A depressed peripheral cellular immune response is related to symptomatic neurocysticercosis. Microbes and Infection, 2006, 8, 1082-1089.	1.0	50
104	An epidemiological study of familial neurocysticercosis in an endemic Mexican community. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 551-558.	0.7	63
105	Taenia solium: the complex interactions, of biological, social, geographical and commercial factors, involved in the transmission dynamics of pig cysticercosis in highly endemic areas. Annals of Tropical Medicine and Parasitology, 2006, 100, 123-135.	1.6	29
106	Relationship between the clinical heterogeneity of neurocysticercosis and the immune-inflammatory profiles. Clinical Immunology, 2005, 116, 271-278.	1.4	97
107	Use of the Capture-Recapture Method for Determining the Prevalence of Neurological Parasitic Diseases: A Reply. Neuroepidemiology, 2004, 23, 100-100.	1.1	1
108	Symptomatic human neurocysticercosis. Journal of Neurology, 2004, 251, 830-7.	1.8	101

#	Article	IF	CITATIONS
109	Population genetic structure of Taenia solium from Madagascar and Mexico: implications for clinical profile diversity and immunological technology. International Journal for Parasitology, 2003, 33, 1479-1485.	1.3	70
110	Detection of secreted cysticercal antigen: a useful tool in the diagnosis of inflammatory neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 542-546.	0.7	34
111	TH2 profile in asymptomatic Taenia solium human neurocysticercosis. Microbes and Infection, 2003, 5, 1109-1115.	1.0	63
112	Application of synthetic peptides to the diagnosis of neurocysticercosis. Tropical Medicine and International Health, 2003, 8, 1124-1130.	1.0	29
113	High Prevalence of Calcified Silent Neurocysticercosis in a Rural Village of Mexico. Neuroepidemiology, 2003, 22, 139-145.	1.1	131
114	Castration and pregnancy of rural pigs significantly increase the prevalence of naturally acquired Taenia solium cysticercosis. Veterinary Parasitology, 2002, 108, 41-48.	0.7	65
115	Neurocysticercosis: validity of ELISA after storage of whole blood and cerebrospinal fluid on paper. Tropical Medicine and International Health, 2001, 6, 688-693.	1.0	17
116	Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes and Infection, 2000, 2, 1875-1890.	1.0	205
117	Cysticercosis: towards the design of a diagnostic kit based on synthetic peptides. Immunology Letters, 2000, 71, 13-17.	1.1	27
118	Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 479-482.	0.9	356
119	Lack of association between human leukocyte antigens and the antiâ€Hu syndrome in patients with smallâ€cell lung cancer. Neurology, 1998, 50, 565-566.	1.5	12
120	Descriptive epidemiology of cerebral gliomas in France. , 1997, 79, 1195-1202.		114
121	Taenia solium. , 0, , 229-243.		1
122	Neuroinflammation: Peripheral and Neurogenic Underlying Processes. Journal of Contemporary Immunology, 0, , .	0.0	0